> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Teva Expands Losartan Recall
- URL: https://www.fdaweb.com/teva-expands-losartan-recall/
- Published: 2019-06-13T12:00:00.000Z
- Updated: 2026-09-15T01:32:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144337

FDA says Teva is expanding a recall to include seven additional lots of losartan potassium tablets, including three lots of 50 mg strength and four lots of 100 mg strength. An agency [notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan?ref=fdaweb.com) says the recall is due to unacceptable amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in the losartan active pharmaceutical ingredient manufactured by Hetero Labs Limited. The notice saysTeva is recalling lots of losartan-containing medication that tested positive for NMBA above 9.82 parts per million, and that FDA updated the list of [recalled angiotensin II receptor blockers ](https://www.fda.gov/drugs/drug-safety-and-availability/search-list-recalled-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and?ref=fdaweb.com)accordingly.